
    
      Each participant will be in the study for approximately 39 weeks including: a 1-week
      screening period, an 8-week (or greater) antihyperglycemic agent (AHA) wash-off period, a
      2-week single-blind placebo run-in period, a 26-week double-blind treatment period, and a
      post-treatment telephone contact 14 days after the last dose of study drug.
    
  